A Study to Evaluate Solrikitug in Participants With COPD (ZION)

Inclusion Criteria:

• At least 40 years of age and no older than 75 years.

• Documented diagnosis of COPD for at least 12 months prior to Screening, defined bythe GOLD Guidelines (2023), and elevated blood eosinophils at screening.

• At Screening FEV1/FVC ratio must be <0.70, and Post-bronchodilator FEV1 must be ≥40%to <80% predicted normal value calculated using Global Lung Function Initiative (GLI) reference equations (Cooper et al 2017).

• Symptomatic (COPD Assessment Test [CAT] Score ≥10) at Screening Visit 1.

• Participants must be on 2 or more inhaled maintenance medications for management oftheir COPD, for at least 3 months prior to screening.

Exclusion Criteria:

• Female participant who is pregnant or breastfeeding.

• Participant has a known hypersensitivity to any component of the formulation ofsolrikitug, including any of the excipients, or a history of anaphylactic reactionto any therapeutic monoclonal antibody.

• Participant has history or evidence of any clinically significant cardiovascular,hematologic, hepatic, immunologic, metabolic, urologic, neurologic, dermatologic,psychiatric, renal and/or other major disease or malignancy, or any other conditionthat in the opinion of the Investigator or Medical Monitor might obfuscate the studydata.

• Any other pulmonary disease than COPD that in the opinion of the Investigator, theseverity of the disorder would impact the conduct of the study.

• Undergone major lung surgery, within 1 year of Screening Visit 1.

• Participant has a lower respiratory tract infection that required antibiotics within 6 weeks prior to Screening.